ライフサイエンスコーパス: to be eligible

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します

1 rmance status of 0 or 1, and at least one measurable lesion to be eligible.

2 The NPAO patients were less likely to be eligible after 9 hours than before 9 hours (17% for >9

3 A total of 33 studies were found to be eligible and included 3 matched case control studies an

4 We screened 1193 patients; 178 were found to be eligible and were randomly assigned to treatment groups

5 o hundred eighty-five (86%) of the patients were determined to be eligible, and 47 (14%) were not eligible.

6 p performance status of 0-2, at least one measurable lesion to be eligible, and who were ineligible for intensive chemoth

7 or further interventions, 9 were certified and 9 were found to be eligible, but declined certification.

8 y 11.9% of ICA+ but GAA- and ICA512AA- relatives were found to be eligible by DPT criteria for trial entry.

9 To be eligible for enrollment, patients had to meet one of th

10 d medical conditions, blacks were significantly less likely to be eligible for HCV treatment.

11 Of 110 studies identified, 25 trials were shown to be eligible for inclusion in the meta-analysis.

12 To be eligible for inclusion, individuals must have been judg

13 To be eligible for inclusion, participants had to have at lea

14 To be eligible for inclusion, participants had to have had de

15 lt travelers were included; providers considered 6612 (16%) to be eligible for MMR vaccine at the time of pretravel consu

16 Racial/ethnic minorities were significantly less likely to be eligible for screening yet had higher odds of developin

17 participate in the study; 1,375 APA members were determined to be eligible for study participation.

18 up I patients had smaller tumors (P =.01), were more likely to be eligible for surgical treatment (P =.005), and had a be

19 To be eligible for the en face OCT subanalysis, the preserved

20 To be eligible for the oral insulin trial, a relative had to

21 To be eligible for the parenteral insulin DPT-1 trial, a rela

22 To be eligible for the review, studies had to describe and re

23 All subjects had to have a diagnosis of colorectal adenoma to be eligible for the trial.

24 ype 1 infection, blacks were 65% less likely than nonblacks to be eligible for treatment (28.1% > 17.0%; relative risk, 1

25 h frontline nivolumab who were clinically stable and judged to be eligible for treatment beyond RECIST v1.1-defined progr

26 Of 572 relatives found to be eligible for trial entry, 442 (77.3%) were positive for

27 To be eligible, participants needed to have access to the int

28 To be eligible, patients had to be aged at least 18 years and

29 To be eligible, studies had to meet three inclusion criteria:

30 However, to be eligible, these patients generally must have a prognosi

31 For a patient to be eligible, tissue microarrays, clinical follow-up data,

32 To be eligible, women had to be at increased risk of breast c

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。